These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 32643356

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
    Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou SK, Simati S, Kouvari M, Kumar A, Kalra B, Kumar M, Bontozoglou N, Kyriakopoulou K, Mantzoros CS.
    Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P, Tziomalos K, Pratilas GC, Makris V, Sotiriadis A, Dinas K.
    Folia Med (Plovdiv); 2018 Dec 01; 60(4):512-520. PubMed ID: 31188761
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Overview of new antiobesity drugs.
    Hainer V.
    Expert Opin Pharmacother; 2014 Oct 01; 15(14):1975-8. PubMed ID: 25100293
    [Abstract] [Full Text] [Related]

  • 9. Weight Loss Pharmacotherapy: Current and Future Therapies.
    Jordan G, Young S, Alemán JO.
    Gastrointest Endosc Clin N Am; 2024 Oct 01; 34(4):591-608. PubMed ID: 39277293
    [Abstract] [Full Text] [Related]

  • 10. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W, Trujillo JM, Megyeri J.
    Ann Pharmacother; 2016 May 01; 50(5):376-88. PubMed ID: 26887340
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.
    Mancini MC, de Melo ME.
    Diabetol Metab Syndr; 2017 May 01; 9():44. PubMed ID: 28580018
    [Abstract] [Full Text] [Related]

  • 16. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM.
    Future Cardiol; 2016 Mar 01; 12(2):129-38. PubMed ID: 26679384
    [Abstract] [Full Text] [Related]

  • 17. Practical Use of Pharmacotherapy for Obesity.
    Igel LI, Kumar RB, Saunders KH, Aronne LJ.
    Gastroenterology; 2017 May 01; 152(7):1765-1779. PubMed ID: 28192104
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacotherapy for obesity].
    van Rossum EFC, Welling MS, van der Voorn B, van der Valk ES, Abawi O, van den Akker ELT.
    Ned Tijdschr Geneeskd; 2021 Jan 19; 165():. PubMed ID: 33560612
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF, Shukla AP, Aronne LJ.
    Expert Rev Clin Pharmacol; 2016 Jan 19; 9(1):27-34. PubMed ID: 26512740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.